Amicus Wins English Funding For Pombiliti/Opfolda, Immunocore To Appeal Kimmtrak Rejection

Amicus is launching its Pompe disease treatment Pombiliti/Opfolda in the UK after announcing on the same day that it had secured reimbursement and marketing approval for the combination treatment. Meanwhile, Immunocore says it disagrees with NICE's rejection of its advanced uveal melanoma drug, Kimmtrak.